Topoisomerase inhibitors US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Topoisomerase inhibitors. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Topoisomerase inhibitors US Medical PG Question 1: A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. The research team decides to conduct a non-randomized study where the novel drug will be offered to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy, while patients without such risk factors will receive the standard treatment. Which of the following best describes the level of evidence that this study can offer?
- A. Level 1
- B. Level 3 (Correct Answer)
- C. Level 5
- D. Level 4
- E. Level 2
Topoisomerase inhibitors Explanation: ***Level 3***
- A **non-randomized controlled trial** like the one described, where patient assignment to treatment groups is based on specific characteristics (risk of toxicity), falls into Level 3 evidence.
- This level typically includes **non-randomized controlled trials** and **well-designed cohort studies** with comparison groups, which are prone to selection bias and confounding.
- The study compares two treatments but lacks randomization, making it Level 3 evidence.
*Level 1*
- Level 1 evidence is the **highest level of evidence**, derived from **systematic reviews and meta-analyses** of multiple well-designed randomized controlled trials or large, high-quality randomized controlled trials.
- The described study is explicitly stated as non-randomized, ruling out Level 1.
*Level 2*
- Level 2 evidence involves at least one **well-designed randomized controlled trial** (RCT) or **systematic reviews** of randomized trials.
- The current study is *non-randomized*, which means it cannot be classified as Level 2 evidence, as randomization is a key criterion for this level.
*Level 4*
- Level 4 evidence includes **case series**, **case-control studies**, and **poorly designed cohort or case-control studies**.
- While the study is non-randomized, it is a controlled comparative trial rather than a case series or retrospective case-control study, placing it at Level 3.
*Level 5*
- Level 5 evidence is the **lowest level of evidence**, typically consisting of **expert opinion** without explicit critical appraisal, or based on physiology, bench research, or animal studies.
- While the drug was initially tested in animal studies, the current human comparative study offers a higher level of evidence than expert opinion or preclinical data.
Topoisomerase inhibitors US Medical PG Question 2: A 61-year-old woman is brought to the emergency department because of fever, chills, and flank pain for 8 hours. Her temperature is 39.1°C (102.4°F). Physical examination shows right costovertebral angle tenderness. Urine dipstick is positive for nitrites. Urinalysis shows gram-negative rods. The patient is admitted to the hospital and treatment with a drug that directly inhibits bacterial DNA replication is begun. This drug inhibits a protein that is normally responsible for which of the following steps of DNA replication?
- A. Excising RNA fragments in 5' to 3' direction
- B. Cleaving DNA to relieve supercoils (Correct Answer)
- C. Binding to single-stranded DNA to prevent reannealing
- D. Unwinding DNA at replication fork
- E. Joining of short DNA fragments
Topoisomerase inhibitors Explanation: ***Cleaving DNA to relieve supercoils***
- The patient's symptoms (fever, chills, flank pain, CVA tenderness, nitrites in urine, gram-negative rods) are consistent with **pyelonephritis**, typically caused by **gram-negative bacteria**.
- The drug described is an **antibiotic** that inhibits bacterial **DNA replication**. This mechanism points towards **fluoroquinolones**, which inhibit **DNA gyrase (topoisomerase II)** and **topoisomerase IV**. These enzymes are responsible for **cleaving DNA** to relieve supercoils during replication and transcription.
*Excising RNA fragments in 5' to 3' direction*
- This function is primarily carried out by **DNA polymerase I** in prokaryotes, which removes **RNA primers** during replication.
- While essential for replication, it is not the direct target of antibiotics that inhibit overall bacterial DNA replication in the described scenario.
*Binding to single-stranded DNA to prevent reannealing*
- This role is performed by **single-stranded binding proteins (SSBs)**, which stabilize the separated DNA strands at the replication fork.
- These proteins are not typically targeted by antibiotics that inhibit DNA replication.
*Unwinding DNA at replication fork*
- The unwinding of DNA at the replication fork is primarily carried out by **DNA helicase**.
- While crucial for replication, antibiotics like fluoroquinolones target different enzymes involved in managing DNA topology.
*Joining of short DNA fragments*
- The joining of Okazaki fragments on the lagging strand is catalyzed by **DNA ligase**.
- This enzyme is not the primary target of antibiotics designed to broadly inhibit bacterial DNA replication by interfering with DNA gyrase or topoisomerase IV.
Topoisomerase inhibitors US Medical PG Question 3: A 71-year-old man with colorectal cancer comes to the physician for follow-up examination after undergoing a sigmoid colectomy. The physician recommends adjuvant chemotherapy with an agent that results in single-stranded DNA breaks. This chemotherapeutic agent most likely has an effect on which of the following enzymes?
- A. DNA polymerase III
- B. Topoisomerase I (Correct Answer)
- C. Helicase
- D. Telomerase
- E. Topoisomerase II
Topoisomerase inhibitors Explanation: ***Topoisomerase I***
- **Topoisomerase I** creates **single-stranded DNA (ssDNA) breaks** to relieve torsional stress during DNA replication and transcription.
- Many chemotherapeutic agents, such as camptothecin and its derivatives (e.g., irinotecan, topotecan), target topoisomerase I, leading to DNA damage and apoptosis in cancer cells.
*DNA polymerase III*
- **DNA polymerase III** is primarily involved in bacterial DNA replication, synthesizing new DNA strands in a 5' to 3' direction.
- While essential for bacterial survival, it is not the target of chemotherapeutic agents that induce single-stranded DNA breaks in human cells.
*Helicase*
- **Helicase** is responsible for unwinding the DNA double helix during replication and transcription, separating the two strands.
- While its function is critical for DNA processes, it does not directly create DNA breaks as its primary mechanism of action.
*Telomerase*
- **Telomerase** is an enzyme that maintains telomere length at the ends of chromosomes, particularly active in cancer cells.
- Inhibitors of telomerase aim to shorten telomeres, leading to cellular senescence or apoptosis, but they do not primarily cause single-stranded DNA breaks.
*Topoisomerase II*
- **Topoisomerase II** creates **double-stranded DNA (dsDNA) breaks** to untangle and decatenate DNA.
- Though also a target for chemotherapy (e.g., etoposide, doxorubicin), its mechanism involves double-stranded breaks, not single-stranded breaks as specified in the question.
Topoisomerase inhibitors US Medical PG Question 4: A 42-year-old man with non-small cell lung cancer is enrolled in a clinical trial for a new chemotherapeutic drug. The drug prevents microtubule depolymerization by binding to the beta subunit of tubulin. The mechanism of action of this new drug is most similar to which of the following?
- A. Bleomycin
- B. Irinotecan
- C. Vincristine
- D. Cladribine
- E. Paclitaxel (Correct Answer)
Topoisomerase inhibitors Explanation: ***Paclitaxel***
- **Paclitaxel** is a **taxane** that stabilizes microtubules by binding to the **beta-tubulin subunit**, preventing their depolymerization and arresting cells in metaphase.
- This mechanism is consistent with the described drug's action of preventing **microtubule depolymerization**.
*Bleomycin*
- **Bleomycin** is an **antitumor antibiotic** that causes **DNA strand breaks** by forming free radicals.
- Its mechanism is entirely different from microtubule stabilization.
*Irinotecan*
- **Irinotecan** is a **topoisomerase I inhibitor** that prevents DNA unwinding, leading to DNA damage and cell death.
- This drug targets DNA replication and repair, not microtubule dynamics.
*Vincristine*
- **Vincristine** is a **vinca alkaloid** that inhibits microtubule formation by binding to **beta-tubulin**, preventing its polymerization (assembly).
- While it also targets microtubules, its action is to *prevent polymerization*, whereas the new drug prevents *depolymerization*.
*Cladribine*
- **Cladribine** is a **purine analog** that inhibits DNA synthesis by incorporating into DNA and RNA, leading to strand breaks and cell death.
- This drug primarily interferes with nucleic acid metabolism, not microtubule function.
Topoisomerase inhibitors US Medical PG Question 5: A 71-year-old woman presents to her hematologist-oncologist for follow up after having begun doxorubicin and cyclophosphamide in addition to radiation therapy for the treatment of her stage 3 breast cancer. Her past medical history is significant for preeclampsia, hypertension, polycystic ovarian syndrome, and hypercholesterolemia. She currently smokes 1 pack of cigarettes per day, drinks a glass of wine per day, and denies any illicit drug use. The vital signs include: temperature 36.7°C (98.0°F), blood pressure 126/74 mm Hg, heart rate 111/min, and respiratory rate 23/min. On physical examination, the pulses are strong and irregular, she has a grade 3/6 holosystolic murmur heard best at the left upper sternal border, clear bilateral breath sounds, and erythema over her site of radiation. Which of the following statements regarding doxorubicin is true?
- A. Doxorubicin has a maximum lifetime dose, due to the risk of cardiac toxicity (Correct Answer)
- B. Doxorubicin has a maximum lifetime dose, due to the risk of pulmonary toxicity
- C. Doxorubicin will increase her risk for deep vein thrombosis (DVT) and pulmonary embolism (PE)
- D. Doxorubicin frequently causes an acneiform rash
- E. Doxorubicin frequently causes cystitis
Topoisomerase inhibitors Explanation: ***Doxorubicin has a maximum lifetime dose, due to the risk of cardiac toxicity***
- **Doxorubicin** is a potent chemotherapy agent (anthracycline) with a well-known risk of **cardiotoxicity**, which can lead to **dilated cardiomyopathy** and heart failure.
- To mitigate this severe side effect, a **cumulative lifetime dose limit** (usually 450-550 mg/m²) is established for doxorubicin.
*Doxorubicin has a maximum lifetime dose, due to the risk of pulmonary toxicity*
- While some chemotherapy agents can cause pulmonary toxicity, **doxorubicin** is not primarily associated with this as its main dose-limiting toxicity.
- The most significant and common dose-limiting toxicity of doxorubicin is **cardiotoxicity**, not pulmonary.
*Doxorubicin will increase her risk for deep vein thrombosis (DVT) and pulmonary embolism (PE)*
- Chemotherapy in general can increase the risk of **thromboembolic events**, but this is not a specific dose-limiting toxicity of **doxorubicin** that dictates a lifetime maximum dose.
- The concern for DVT/PE is a broader complication of cancer and its treatment, distinct from doxorubicin's specific cardiac risk.
*Doxorubicin frequently causes an acneiform rash*
- **Acneiform rash** is a common side effect of epidermal growth factor receptor (EGFR) inhibitors (e.g., cetuximab, erlotinib), not typically associated with **doxorubicin**.
- Doxorubicin's dermatologic side effects usually involve **alopecia**, hand-foot syndrome, and radiation recall, but not a predominant acneiform rash.
*Doxorubicin frequently causes cystitis*
- **Cystitis**, particularly hemorrhagic cystitis, is a well-known side effect of **cyclophosphamide** (another drug the patient is receiving), not **doxorubicin**.
- **Mesna** is often administered with cyclophosphamide to prevent this urological toxicity.
Topoisomerase inhibitors US Medical PG Question 6: A 53-year-old woman comes to the physician because of increasing shortness of breath on exertion for 5 months. She reports that she can not climb more than 2 flights of stairs and she is no longer able to run her errands as usual. One year ago, she was diagnosed with triple-negative breast cancer. She underwent a right-sided modified radical mastectomy and adjuvant chemotherapy. Cardiac examination shows a laterally displaced point of maximal impulse. Coarse inspiratory crackles are heard in both lower lung fields. Echocardiography shows a left ventricular ejection fraction of 30%. The physician informs the patient that her symptoms are most likely due to an adverse effect of her chemotherapy. The drug most likely responsible for the patient's current symptoms belongs to which of the following groups of agents?
- A. Antimetabolites
- B. Monoclonal antibodies
- C. Alkylating agents
- D. Topoisomerase I inhibitors
- E. Anthracyclines (Correct Answer)
Topoisomerase inhibitors Explanation: ***Anthracyclines***
- The patient's presentation of **dilated cardiomyopathy** (shortness of breath, laterally displaced PMI, coarse crackles, reduced ejection fraction) following chemotherapy for breast cancer is characteristic of **anthracycline-induced cardiotoxicity**.
- **Anthracyclines** such as doxorubicin and epirubicin are known to cause **dose-dependent cardiotoxicity**, leading to irreversible myocardial damage and heart failure.
*Antimetabolites*
- **Antimetabolites** (e.g., methotrexate, 5-fluorouracil) primarily interfere with DNA synthesis and repair.
- While they can have side effects like myelosuppression and mucositis, **significant cardiotoxicity** leading to dilated cardiomyopathy is not their primary or most common adverse effect.
*Monoclonal antibodies*
- Some **monoclonal antibodies**, particularly trastuzumab (Herceptin), used in HER2-positive breast cancer, can cause cardiotoxicity, but it is typically **reversible** and not seen with triple-negative breast cancer unless used in combination with anthracyclines.
- The type of cardiomyopathy with trastuzumab is usually **reversible cardiac dysfunction** rather than irreversible dilated cardiomyopathy.
*Alkylating agents*
- **Alkylating agents** (e.g., cyclophosphamide, cisplatin) primarily damage DNA, leading to cell death.
- While they can cause various side effects, **dilated cardiomyopathy** is not a hallmark or common cardiotoxic effect, unlike anthracyclines, though high-dose cyclophosphamide can cause acute pericarditis or myocarditis.
*Topoisomerase I inhibitors*
- **Topoisomerase I inhibitors** (e.g., irinotecan, topotecan) typically cause gastrointestinal side effects (diarrhea), myelosuppression, and fatigue.
- **Cardiotoxicity** leading to dilated cardiomyopathy is not a prominent or common side effect associated with this class of drugs.
Topoisomerase inhibitors US Medical PG Question 7: A 62-year-old woman presents to her oncologist to discuss the chemotherapy options for her newly diagnosed breast cancer. During the meeting, they discuss a drug that inhibits the breakdown of mitotic spindles in cells. Her oncologist explains that this will be more toxic to cancer cells because those cells are dividing more rapidly. Which of the following side effects is closely associated with the use of this chemotherapeutic agent?
- A. Photosensitivity
- B. Peripheral neuropathy (Correct Answer)
- C. Paralytic ileus
- D. Hemorrhagic cystitis
- E. Pulmonary fibrosis
Topoisomerase inhibitors Explanation: ***Peripheral neuropathy***
- Drugs that inhibit the breakdown of **mitotic spindles** are **microtubule-targeting agents** (e.g., **taxanes** like paclitaxel/docetaxel, **vinca alkaloids** like vincristine/vinblastine).
- These agents interfere with **microtubule function** in neurons, leading to **axonal damage** and **peripheral neuropathy**.
- This is the **most characteristic and common dose-limiting toxicity** of microtubule inhibitors, affecting sensory and motor nerves (numbness, tingling, weakness in extremities).
*Photosensitivity*
- **Photosensitivity** is a common adverse effect associated with certain chemotherapeutic agents like **fluorouracil** (5-FU) or **methotrexate**, but is not linked to microtubule inhibitors.
- It involves an increased sensitivity to UV light, often manifesting as a rash or exaggerated sunburn.
*Paralytic ileus*
- **Paralytic ileus** can occur with **vinca alkaloids** (especially vincristine) due to autonomic neuropathy affecting the **enteric nervous system**.
- However, this is **less common** than peripheral neuropathy and occurs more specifically with vincristine rather than taxanes.
- **Peripheral neuropathy** is the more pervasive, dose-limiting, and universally characteristic side effect across all microtubule inhibitors.
*Hemorrhagic cystitis*
- **Hemorrhagic cystitis** is a classic side effect of **alkylating agents** like **cyclophosphamide** and **ifosfamide**, which produce the toxic metabolite **acrolein**.
- It is prevented/managed with **mesna**, which inactivates acrolein.
- Not associated with microtubule inhibitors.
*Pulmonary fibrosis*
- **Pulmonary fibrosis** is a known side effect of certain chemotherapeutic drugs, most notably **bleomycin** and **busulfan**.
- This adverse effect is not associated with agents that target **mitotic spindle breakdown**.
Topoisomerase inhibitors US Medical PG Question 8: An epidemiologist is evaluating the efficacy of Noxbinle in preventing HCC deaths at the population level. A clinical trial shows that over 5 years, the mortality rate from HCC was 25% in the control group and 15% in patients treated with Noxbinle 100 mg daily. Based on this data, how many patients need to be treated with Noxbinle 100 mg to prevent, on average, one death from HCC?
- A. 20
- B. 73
- C. 10 (Correct Answer)
- D. 50
- E. 100
Topoisomerase inhibitors Explanation: ***10***
- The **number needed to treat (NNT)** is calculated by first finding the **absolute risk reduction (ARR)**.
- **ARR** = Risk in control group - Risk in treatment group = 25% - 15% = **10%** (or 0.10).
- **NNT = 1 / ARR** = 1 / 0.10 = **10 patients**.
- This means that **10 patients must be treated with Noxbinle to prevent one death from HCC** over 5 years.
*20*
- This would result from an ARR of 5% (1/0.05 = 20), which is not supported by the data.
- May arise from miscalculating the risk difference or incorrectly halving the actual ARR.
*73*
- This value does not correspond to any standard calculation of NNT from the given mortality rates.
- May result from confusion with other epidemiological measures or calculation error.
*50*
- This would correspond to an ARR of 2% (1/0.02 = 50), which significantly underestimates the actual risk reduction.
- Could result from incorrectly calculating the difference as a proportion rather than absolute percentage points.
*100*
- This would correspond to an ARR of 1% (1/0.01 = 100), grossly underestimating the treatment benefit.
- May result from confusing ARR with relative risk reduction or other calculation errors.
Topoisomerase inhibitors US Medical PG Question 9: A 54-year-old woman is diagnosed with locally-advanced invasive ductal carcinoma of the breast. She undergoes surgical resection, radiation therapy, and is now being started on adjunctive chemotherapy with cyclophosphamide and doxorubicin. The patient is scheduled for follow up by her primary care provider. Which of the following tests should be performed regularly to monitor her current treatment regimen?
- A. No regular monitoring indicated
- B. Chest radiograph
- C. Cardiac MRI
- D. ECG
- E. Echocardiography (Correct Answer)
Topoisomerase inhibitors Explanation: ***Echocardiography***
- **Doxorubicin** is an anthracycline chemotherapy agent known for its dose-dependent **cardiotoxicity**, which can lead to **dilated cardiomyopathy** and heart failure.
- Regular echocardiography is crucial to monitor **left ventricular ejection fraction (LVEF)** and detect early signs of cardiac dysfunction, allowing for timely intervention or adjustment of treatment.
*No regular monitoring indicated*
- This is incorrect as **doxorubicin**, a component of the chemotherapy regimen, has significant cardiotoxic effects that require close monitoring to prevent severe cardiac complications.
- Neglecting monitoring could lead to irreversible cardiac damage.
*Chest radiograph*
- A chest radiograph primarily assesses lung fields and cardiac silhouette, but it is not sensitive enough to detect early-stage **doxorubicin-induced myocardial damage** or changes in **LVEF**.
- While useful for detecting pulmonary complications or metastases, it is not the primary tool for monitoring cardiotoxicity.
*Cardiac MRI*
- Cardiac MRI is a highly sensitive and specific imaging modality for assessing cardiac function and structure, but it is typically reserved for cases where echocardiography findings are equivocal or more detailed assessment is needed.
- It is not the routine or initial test for monitoring cardiotoxicity due to its higher cost and complexity.
*ECG*
- An ECG assesses the electrical activity of the heart and can detect arrhythmias or signs of ischemia, but it is generally not sufficient for monitoring **doxorubicin-induced cardiotoxicity**.
- While it can show nonspecific changes, it does not directly measure changes in **LVEF** or structural heart damage, which are key indicators of cardiotoxicity.
Topoisomerase inhibitors US Medical PG Question 10: A 17-year-old woman is rushed into the emergency department by her father who found her collapsed in her bedroom 15 minutes before the ambulance's arrival. There was an empty bottle of clomipramine in her bedroom which her mother takes for her depression. Vital signs include the following: respiratory rate 8/min, pulse 130/min, and blood pressure 100/60 mm Hg. On physical examination, the patient is unresponsive to vocal and tactile stimuli. Oral mucosa and tongue are dry, and the bladder is palpable. A bedside electrocardiogram (ECG) shows widening of the QRS complexes. Which of the following would be the best course of treatment in this patient?
- A. Norepinephrine
- B. Sodium bicarbonate (Correct Answer)
- C. Diazepam
- D. Lidocaine
- E. Induced vomiting
Topoisomerase inhibitors Explanation: ***Sodium bicarbonate***
- The patient presents with classic signs of **tricyclic antidepressant (TCA) overdose**, including coma, tachycardia, hypotension, dry oral mucosa (anticholinergic effects), urinary retention, and significantly, **widened QRS complexes** on ECG.
- **Sodium bicarbonate** is the treatment of choice for TCA overdose-induced cardiotoxicity, as it alkalinizes the blood, reducing the binding of TCAs to myocardial fast sodium channels and improving cardiac conduction.
- The primary indication is **QRS widening >100 ms**, which indicates severe sodium channel blockade and increased risk of ventricular arrhythmias.
*Norepinephrine*
- While the patient is hypotensive, **norepinephrine** (a vasopressor) primarily addresses blood pressure and not the underlying cardiotoxicity or arrhythmias caused by TCA overdose.
- Using vasopressors without addressing the membrane-stabilizing effects of TCAs on the heart may not resolve the critical cardiac issues.
- Sodium bicarbonate should be administered first to address the cardiotoxicity.
*Diazepam*
- **Diazepam** is a benzodiazepine used to treat seizures or agitation, which can sometimes occur in TCA overdose.
- However, it does not address the vital signs or the severe cardiotoxicity (widened QRS) which is the most life-threatening complication here.
*Lidocaine*
- **Lidocaine** is an antiarrhythmic drug; however, it is relatively contraindicated in TCA overdose as it blocks cardiac sodium channels, which could worsen the existing sodium channel blockade caused by TCAs.
- This could exacerbate QRS widening and increase the risk of malignant arrhythmias.
*Induced vomiting*
- **Induced vomiting** (e.g., with ipecac syrup) is contraindicated in cases of overdose, particularly with altered mental status, due to the high risk of **aspiration pneumonitis**.
- In a patient who is unresponsive, attempts at gastric decontamination via emesis are dangerous and ineffective.
More Topoisomerase inhibitors US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
